Your browser doesn't support javascript.
loading
The VASCERN-VASCA working group diagnostic and management pathways for severe and/or rare infantile hemangiomas.
Diociaiuti, Andrea; Baselga, Eulalia; Boon, Laurence M; Dompmartin, Anne; Dvorakova, Veronika; El Hachem, May; Gasparella, Paolo; Haxhija, Emir; Ghaffarpour, Nader; Kyrklund, Kristiina; Irvine, Alan D; Kapp, Friedrich G; Rößler, Jochen; Salminen, Päivi; van den Bosch, Caroline; van der Vleuten, Carine; Kool, Leo Schultze; Vikkula, Miikka.
Afiliación
  • Diociaiuti A; Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio 4, 00165, Rome, Italy. Electronic address: andrea.diociaiuti@opbg.net.
  • Baselga E; Pediatric Dermatology, Hospital Sant Joan de Deu, Barcelona, Spain.
  • Boon LM; Center for Vascular Anomalies, Division of Plastic Surgery, University Clinics Saint-Luc, University of Louvain, VASCERN VASCA European Reference Centre, Brussels, Belgium.
  • Dompmartin A; Department of Dermatology, Université de Caen Basse Normandie, CHU Caen, Caen, France.
  • Dvorakova V; Paediatric Dermatology, Children's Health Ireland, (y)Clinical Medicine, Trinity College Dublin, Ireland.
  • El Hachem M; Dermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio 4, 00165, Rome, Italy.
  • Gasparella P; Department of Paediatric and Adolescent Surgery, Medical University of Graz, Graz, Austria.
  • Haxhija E; Department of Paediatric and Adolescent Surgery, Medical University of Graz, Graz, Austria.
  • Ghaffarpour N; Department of Plastic- and Craniofacial Surgery, Karolinska University Hospital, Stockholm, Sweden.
  • Kyrklund K; Department of Pediatric Surgery, HUS Rare Disease Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Irvine AD; Paediatric Dermatology, Children's Health Ireland, (y)Clinical Medicine, Trinity College Dublin, Ireland.
  • Kapp FG; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany.
  • Rößler J; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern
  • Salminen P; Department of Pediatric Surgery, HUS Rare Disease Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • van den Bosch C; Hevas, Patient Organisation for Vascular Anomalies, the Netherlands.
  • van der Vleuten C; Department of Dermatology, Radboudumc Expertise Center for Haemangiomas and Congenital Vascular Malformations Nijmegen Hecovan, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Kool LS; Department of Radiology, Radboudumc Expertise Center for Haemangiomas and Congenital Vascular Malformations Nijmegen Hecovan, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Vikkula M; Center for Vascular Anomalies, Division of Plastic Surgery, University Clinics Saint-Luc, University of Louvain, VASCERN VASCA European Reference Centre, Brussels, Belgium; Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium.
Eur J Med Genet ; 65(6): 104517, 2022 Jun.
Article en En | MEDLINE | ID: mdl-35487416
ABSTRACT
The European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), is dedicated to gathering the best expertise in Europe and provide accessible cross-border healthcare to patients with rare vascular diseases. Infantile Hemangiomas (IH) are benign vascular tumors of infancy that rapidly growth in the first weeks of life, followed by stabilization and spontaneous regression. In rare cases the extent, the localization or the number of lesions may cause severe complications that need specific and careful management. Severe IH may be life-threatening due to airway obstruction, liver or cardiac failure or may harbor a risk of functional impairment, severe pain, and/or significant and permanent disfigurement. Rare IHs include syndromic variants associated with extracutaneous abnormalities (PHACE and LUMBAR syndromes), and large segmental hemangiomas. There are publications that focus on evidence-based medicine on propranolol treatment for IH and consensus statements on the management of rare infantile hemangiomas mostly focused on PHACES syndrome. The Vascular Anomalies Working Group (VASCA-WG) decided to develop a diagnostic and management pathway for severe and rare IHs with a Nominal Group Technique (NGT), a well-established, structured, multistep, facilitated group meeting technique used to generate consensus statements. The pathway was drawn following two face-to-face meetings and in multiple web meetings to facilitate discussion, and by mail to avoid the influence of most authoritative members. The VASCA-WG has produced this opinion statement reflecting strategies developed by experts and patient representatives on how to approach patients with severe and rare IH in a practical manner; we present an algorithmic view of the results of our work.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Enfermedades Vasculares / Hemangioma Tipo de estudio: Diagnostic_studies / Qualitative_research Límite: Humans / Infant País/Región como asunto: Europa Idioma: En Revista: Eur J Med Genet Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Enfermedades Vasculares / Hemangioma Tipo de estudio: Diagnostic_studies / Qualitative_research Límite: Humans / Infant País/Región como asunto: Europa Idioma: En Revista: Eur J Med Genet Asunto de la revista: GENETICA MEDICA Año: 2022 Tipo del documento: Article